Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

PROSHARES TRUST (ZBIO) Net Income towards Common Stockholders: 2023-2025

Historic Net Income towards Common Stockholders for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to -$51.5 million.

  • Zenas BioPharma's Net Income towards Common Stockholders fell 33.40% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$193.8 million, marking a year-over-year decrease of 50.07%. This contributed to the annual value of -$161.3 million for FY2024, which is 334.62% down from last year.
  • According to the latest figures from Q3 2025, Zenas BioPharma's Net Income towards Common Stockholders is -$51.5 million, which was up 1.39% from -$52.2 million recorded in Q2 2025.
  • Over the past 5 years, Zenas BioPharma's Net Income towards Common Stockholders peaked at $35.6 million during Q3 2023, and registered a low of -$56.5 million during Q4 2024.
  • Over the past 3 years, Zenas BioPharma's median Net Income towards Common Stockholders value was -$38.0 million (recorded in 2024), while the average stood at -$31.9 million.
  • Data for Zenas BioPharma's Net Income towards Common Stockholders shows a maximum YoY tumbled of 208.37% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Zenas BioPharma's Net Income towards Common Stockholders stood at -$24.8 million in 2023, then slumped by 128.15% to -$56.5 million in 2024, then slumped by 33.40% to -$51.5 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$51.5 million for Q3 2025, versus -$52.2 million for Q2 2025 and -$33.6 million for Q1 2025.